CRO Services Products & Reviews

HistologiX is a leading GLP/GCP accredited Contract Research Organisation based in the UK specialising in Histology, Immunohistochemistry (IHC) and Digital Pathology services. HistologiX works with a broad range of clients from big pharma to small and medium biotech companies worldwide. Our team of scientists have in excess of 120 years combined experience and a customer retention rate of 80%. 

The SomaScan™ 11K Assay Services employ a highly multiplexed, sensitive, quantitative, and reproducible proteomic platform that profiles up to 11,000 human protein measurements in diverse sample types and species – without enrichment or depletion. Ideal for biomarker discovery, it supports basic, translational, pre-clinical, and clinical research across a wide range of diseases.

KREX™ i-Ome™ Discovery Services enable highly multiplexed autoantibody profiling for rapid, reproducible discovery across diverse diseases. The platform measures antibody binding to 1,800+ full-length, correctly folded human proteins – preserving conformational epitopes for highly specific and biologically relevant autoantibody detection. It provides valuable insight into immune responses in health, disease and treatment.

BioIVT offers high quality, normal and disease state, fresh mobilized and cryopreserved leukopaks, custom collected or sourced from extensive inventory, featuring a diverse donor pool including over 600 HLA-typed recallable, consented donors near biotech hubs in the US and UK.

Isolated immune cells play a crucial role across the stages of drug discovery and development from biomarker and target identification through screening and safety assessment to manufacturing. They can be used to create disease models, cell lines, gene editing techniques and more.

With decades of drug metabolism, drug-drug interactions (DDI) and related expertise, BioIVT’s experts can provide you with the right studies to understand the properties and potential risks of your compound when it’s most critical for your program.

Our Metabolite Identification service for peptides utilizes HRMS to characterize peptide metabolism (e.g., hydrolysis, oxidation, glucuronidation). The assay identifies and semi-quantifies metabolites in plasma/tissues, enabling ADME profiling (clearance, bioavailability), toxicity screening (reactive metabolites) and peptide optimization (PK/PD enhancement). Integrated with preclinical data, it supports metabolically stable p…

Our Comprehensive In Vitro Proarrhythmia Assay (CiPA) service assesses proarrhythmic potential of compounds beyond hERG inhibition, integrating effects on multiple cardiac ion channels and human iPSC-derived cardiomyocytes via patch clamp and multi-well MEA platforms. Aligned with FDA's CiPA initiative and ICH E14/S7B guidelines, it predicts QT prolongation and TdP risks for enhanced specificity in early drug safety evaluation…

Our Protein Binding Platform assesses drug-protein interactions using equilibrium dialysis and ultracentrifugation methods to determine unbound fractions and distribution in biological samples including plasma, blood, tissues, and cells. This essential ADME service evaluates reversible drug transfer between compartments, providing insights into pharmacokinetics, bioavailability, and potential interactions.

Our hERG Safety Screening service employs the Synchropatch-384 automated patch clamp system to assess compound effects on the hERG potassium channel. This high-throughput assay detects inhibitors that may prolong QT intervals and cause arrhythmias, aiding early drug safety evaluation. With precise data under physiological conditions, it supports regulatory compliance to advance safer therapeutics. 

Our Metabolite Identification service employs HRMS /LC-MS/MS to decode degradation pathways of antisense oligonucleotides (ASOs), siRNAs, and modified variants, identifying chain-shortened metabolites (5’/3’ cleavage), phosphorothioate changes (desulfurization, inversion) and base/nucleotide alterations (deamination/depurination). Through plasma/tissue/cell analysis, we reveal metabolic stability, biodistribution, and exonucle…

Our Metabolite Identification service for Antibody-Drug Conjugates (ADCs) applies immuno-capture and HRMS to detect payload-containing catabolites, linker cleavages, and biotransformations in biological samples. This targeted assay quantifies free payloads, metabolites, and intact conjugates, assessing stability and off-target risks. Essential for ADC development, it informs payload design and pharmacokinetics, ensuring compli…

Our Cassette and Discrete PK Study service evaluates pharmacokinetic profiles of small molecules in key preclinical species: rat, mouse, dog, and monkey. It uses cassette dosing for high-throughput screening of multiple compounds simultaneously and discrete dosing for precise individual assessments for ADME parameters. This aids in early drug optimization, predicting human PK, and ensuring regulatory compliance for safer candi…

Accelerate precision oncology with Crown Bioscience’s high-quality human biospecimens—comprehensive, clinically annotated samples including tumor tissue, plasma, and PBMCs, optimized for multi-omics research and biomarker discovery.

Accelerate Drug Discovery with Crown Bioscience's Comprehensive DMPK / ADME Services

Cell Line-Derived Xenograft Models, Established multiple in vivo assay systems to evaluate novel anticancer compounds, with each assay specifically designed to understand a drug's mechanism of action, or an individual agent property.

Delve into biomarker discovery and drug development with Crown Bioscience’s next-generation proteomics services—leveraging 4D-DIA technology for deep, reproducible protein profiling and post-translational modification analysis.

Unlock immune insights with Crown Bioscience’s high-throughput flow cytometry—precisely characterize immune cell populations across tissues to elucidate drug mechanisms, assess pharmacodynamics, and optimize immunotherapies.

Accelerate the development of your immuno-oncology drugs with Crown Bioscience’s large panel of immunocompetent syngeneic models.

Crown Bioscience’s preclinical biomarker services help identify, validate, and analyze biomarkers across diverse in vitro and in vivo cancer models. Using multi-omics platforms and expert bioinformatics, these services support drug mechanism studies, patient stratification, and companion diagnostic development to guide oncology drug discovery.

PDX Models Empower your research with models that reflect today’s patients and treatments.

Unlock deeper insights into tissue organization and cellular interactions with Crown Bioscience’s spatial biology and digital pathology services, featuring advanced imaging, automated analysis, and high-throughput biomarker screening for applications in cancer research, immunology, and more.

OrganoidXplore™, Organoid Panel Screening Service

Explore your translational research with Crown Bioscience’s comprehensive genomics services—offering PCR/qPCR, next-generation sequencing, and advanced bioinformatics to deliver high-quality, reproducible data for biomarker discovery and drug development.

Express proteins—even large and challenging constructs—and conduct screening studies directly in HEK293 cells using efficient, reliable TARGATT™ large knock-in technology. With the ability to efficiently and site-specifically insert 20+ kb of DNA (more with nested reactions) into the reliable H11 safe harbor site, TARGATT™ HEK293 kits move you to the next inflection point faster.